UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **March 20, 2023**

Catalyst Biosciences, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	**000-51173**	**56-2020050**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

611 Gateway Blvd **Suite 120** **South San Francisco, CA**	**94080**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: **(650) 871-0761**
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CBIO	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On March 20, 2023, Dr. Nassim Usman, on behalf of Catalyst Biosciences, Inc. (the "Company"), gave a presentation (the "Corporate Presentation"). In addition, the Company posted the Corporate Presentation on its website, ir.catalystbiosciences.com. A copy of the Corporate Presentation is attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number	Description
99.1	Catalyst Biosciences March 20, 2023 Corporate Presentation Slide Deck.
104	Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CATALYST BIOSCIENCES, INC.

Date: March 20, 2023

By: /s/ Nassim Usman, Ph.D.
Nassim Usman, Ph.D.
President and Chief Executive Officer

Exhibit 99.1

CATALYST BIOSCIENCES

Corporate Presentation

20 March 2023

CatalystBiosciences.com

Cautionary Note Regarding Forward-Look

This presentation contains “forward-looking statements” within the meaning
statements involve substantial risks and uncertainties and are based on esti
statements of historical facts, all statements included in this presentation are
without limitation, the amount and timing of planned cash distributions under
the (“CVR”); expectations regarding the proposed transactions with entities a
Beijing Continent Pharmaceuticals Co. Ltd. (“Beijing Continent”), the expecte
the proposed transaction; the potential market opportunity for and expected
nonalcoholic steatohepatitis (“NASH”) and liver fibrosis; the safety and tolera
association of clinical data with potential clinical benefit; and statements rega
regarding, Beijing Continent’s programs. In some cases, you can identify for
as “anticipate,” “design,” “expect,” “potential,” “plan,” or the negative of these
intended to identify forward-looking statements. Actual results or events coul
intentions, expectations, and projections disclosed in the forward-looking sta
cause actual results or events to differ materially, including, but not limited to
combination with Beijing Continent will not be completed in a timely manner,
Hydronidone (F351) in NASH and liver fibrosis will not be successful or requ
that results from the Phase 2 trial of Hydronidone (F351) in hepatitis related
subsequent trials, and other risks described in the "Risk Factors" section of t
Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Sec
(“SEC”) as well as the proxy statement and registration statement on Form S
We disclaim any obligation to update any forward-looking statements, excep

CBIO corporate strategy

Generate further value for stockholders

December 2022

+ Acquired global rights (excluding China) to Hydronic treat NASH and liver fibrosis
+ Plan to acquire a controlling interest in Beijing Conti biopharmaceutical company based in China, from th parties
+ Announced $7.5 million special dividend and CVR

2023

+ Completed $6 million asset sale of compounds desi disorders to GC Biopharma, with net proceeds to be
+ Annual Meeting of Stockholders expected to be held

CBIO 2023 corporate strategy

Transition Our Focus to Organ Fibrosis

+ Expect to consummate Beijing Continent business co
+ Planning development of Hydronidone (F351) for NA
+ Beijing Continent expected to complete enrollment of (F351) for hepatitis B virus (“HBV”)-associated liver fi
+ Distribute remaining net cash from legacy assets to C

Beijing Continent sales of ETUARY (Pirfer

Consistent growth in revenue & profit

Beijing Continent Financials

(Legal entity, local currency)

P/L	000s RMB				
	FY2020	FY2021	FY2022	20 vs 21	21 vs 22
Revenue	447,002	571,038	688,630	28%	21%
COGS	26,627	25,629	29,299	-4%	14%
Gross profit	420,375	545,409	659,331	30%	21%
SG&A	228,460	314,799	413,936*	38%	31%
R&D	37,212	46,188	53,768	24%	16%
Profit before tax	156,656	188,704	194,193	20%	3%
Profit after tax	127,927	149,387	151,594	17%	1%
Headcount	419	481	523	15%	9%

*including writing down of BC's one-time listing expenses of JPY 395M

Catalyst Biosciences

Liver fibrosis market opportunity

Liver fibrosis is the build-up of scar tissue in the liver due to chronic liver damage



Main indications

- Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
- Chronic viral hepatitis B and C
- Alcohol-related liver disease
- Autoimmune hepatitis
- Others: PBC, PSC, Hemochromatosis, Wilson's, Alpha-1 deficiency & other liver injuries/diseases

Treatment algorithm

- Treating the underlying cause
- Medications to prevent, slow or reverse fibrosis
- (End stage) Liver transplantation

Available treatments

- Antivirals for chronic hepatitis B and C
- Immunosuppressants
- Ursodeoxycholic acid
- Corticosteroids, pentoxifylline, and N-acetylcysteine
- ACE inhibitors, Obeticholic acid, and fibrates

Global Liver Fibrosis Treatment Market

$2.7B
USD 2022 est

CAGR
13%
(2023-2030)

Regional Market Share



Drivers

1. High & rising prevalence of liver fibrosis
2. Development of novel therapies
3. Government initiatives and funding

Restraints

1. High cost of treatment
2. Limited efficacy of available treatments
3. Stringent regulatory requirements

Hydronidone's metabolic profile *vs* Pirfeni

Pirfenidone



Hydron

- Low potential of Hydronidone and its major metabolites for DDIs in te CYP450, and major transporter systems
- In contrast to Pirfenidone, the shift toward Phase II metabolism may formation of reactive metabolites and covalent protein binding, thus r idiosyncratic liver toxicity (*Zhou S et al, J Med Chem 2020*)

Hydronidone's (F351) positive nonclinical

Therapeutic effect & favorable safety profile in liver

+ Has shown anti-fibrotic effects across standard models of liv
  - More potent than Pirfenidone
+ Pleiotropic mechanism of action designed to target the key
  - Independent of initial causative insult
  - Results in inhibition of hematopoietic stem cell proliferation wi
+ Absorption, distribution, metabolism and excretion profile is bioavailability, exposure and metabolite profile relevant to h
+ No adverse effects on major organ systems observed
+ Well tolerated upon long-term dosing across species at exp major organ toxicity
+ No genotoxicity or adverse effects on fertility and reproducti

Phase 2 trial results in HBV-induced liver f

Double blind, randomized, placebo-controlled + sta

Design	▪ A randomized, double-blind, placebo-contro dose-exploration phase 2 trial of Hydronidon treatment of liver fibrosis associated with HE Beijing Continent)
Basic Treatment	▪ *Entecavir administered continuously for 52
Primary Endpoint	▪ Proportion of liver fibrosis Ishak scores decr 52 weeks of treatment
Secondary Endpoint	▪ Conversion rate and decrease of HBV DNA ▪ Proportion of decrease in liver transient elas compared to pre-treatment ▪ Proportion of liver tissue inflammation gradir treatment compared to pre-treatment withou ▪ Improvement of liver function alanine aminot

Cai *et al* Clinical Gastroenterology & Hepatol

Phase 2 trial results in HBV-induced liver f

Double blind, randomized, placebo-controlled + ent



Cai *et al* Clinical Gastroenterology & Hepatol

Phase 2 trial results in HBV-induced liver f

Double blind, randomized, placebo-controlled + ent

Therapeutic Effect

Primary Endpoint:
The proportion of Ishak of liver fibrosis decreased by ≥1 point (fibrosis regression) from baseline after 52 weeks treatment

P = 0.024

Safety Profile

Positive safety profile. There was **no statistical difference** in the occurrence of adverse events, adverse reactions and serious adverse events between the four groups during the trial

Cai *et al* Clinical Gastroenterology & Hepatol

Clinical risk/benefit profile of Hydronidone

Potential treatment of liver fibrosis of different etiol

+ Positive results in a subpopulation of patients with sig
  Hydronidone's (F351) potential in preventing progress
+ No statistical difference in the occurrence of adverse
  or serious adverse events between the four groups du
+ Good safety profile demonstrated in subjects with mil
+ No adverse effects nor prolongation of QT interval
+ Food consumption slows down absorption of Hydroni
  metabolites and reduces the Cmax values; therefore,
  recommended
  - No clinically relevant DDIs observed

CBIO Summary

Transitioning Our Focus to Organ Fibrosis

+ Acquired global rights (excluding China) to Hydronido
  treat NASH and liver fibrosis and demonstrating prom
+ Anticipate completing a business combination with Be
  stage biopharmaceutical company based in China in
+ Hydronidone (F351) clinical readouts expected in 202
  and NASH
+ Planned additional cash distributions to CVR holders

Thank you

Nasdaq: CBIO

CatalystBiosciences.com